EGFR and non-small cell lung carcinoma: Despite its limitations, the results of this investigation show that Osimertinib significantly prolonged PFS and OS, raised ORR and DCR, and decreased the incidence of grade 3 or greater AEs in advanced NSCLC patients with common EGFR mutations compared with EGFR-TKIs/chemotherapy.